PARP1 and asthma: PARPi treatment or genetic inactivation (knockout) of PARP-1 suppresses acute and chronic inflammation in organ-specific models (colitis, experimental allergic encephalopathy, dermatitis, arthritis, hepatitis, pancreatitis, asthma, etc.)and generalized inflammation (e.g., septic, endotoxin, or flagellin shock) [6,11,92,93,94,95,96,97,98,99,100,101,102,103,104,105].